MetaVia to Present at Upcoming Investor and Industry Conferences

Rhea-AI Summary

MetaVia (Nasdaq: MTVA), a clinical-stage biotech company specializing in cardiometabolic diseases, has announced its participation in several upcoming investor and industry conferences from September to October 2025.

CEO Hyung Heon Kim will attend the Wells Fargo Healthcare Conference (Sept 3-5), participate in a fireside chat at the H.C. Wainwright Global Investment Conference (Sept 8-10), present at the Obesity Science & Innovation Congress (Sept 16-17), and attend the Fierce Biotech Week (Oct 7-9). At the Obesity Science conference, Kim will showcase DA-1726, the company's dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity treatment.

CAMBRIDGE, Mass., Aug. 26, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.

• September 3-5: Wells Fargo Healthcare Conference. Hyung Heon Kim, President and Chief Executive Officer will attend this conference in Boston, Massachusetts.
  
  
• September 8-10: H.C. Wainwright 27^th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view beginning Friday, September 5, 2025, at 7:00 am ET on the H.C. Wainwright Conference Portal and on the Event Calendar page of the MetaVia website https://ir.metaviatx.com/events-presentations/event-calendar.
  
  Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.
  
  
• September 16-17: Obesity Science & Innovation 2025 Congress. Mr. Kim will present a company overview with a focus on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity, at this conference in Boston, Massachusetts.
  
  
• October 7-9: Fierce Biotech Week. Mr. Kim will attend this conference in Boston, Massachusetts.

To schedule a meeting with management outside of these events, investors can contact Michael Miller at mmiller@rxir.com.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-present-at-upcoming-investor-and-industry-conferences-302536713.html

SOURCE MetaVia Inc.

FAQ

When is MetaVia (MTVA) presenting at the H.C. Wainwright Conference 2025?

MetaVia's on-demand presentation will be available starting September 5, 2025, at 7:00 am ET on both the H.C. Wainwright Conference Portal and MetaVia's website.

What is MetaVia's (MTVA) drug candidate DA-1726?

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), being developed for obesity treatment.

Which conferences will MetaVia (MTVA) attend in September 2025?

MetaVia will attend the Wells Fargo Healthcare Conference (Sept 3-5), H.C. Wainwright Global Investment Conference (Sept 8-10), and Obesity Science & Innovation Congress (Sept 16-17).

How can investors schedule meetings with MetaVia (MTVA) management?

Investors can contact Michael Miller at mmiller@rxir.com to schedule meetings outside of the conference events.